financetom
Business
financetom
/
Business
/
Metro Q3 Adjusted Earnings, Sales Advance, but Miss Estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Metro Q3 Adjusted Earnings, Sales Advance, but Miss Estimates
Aug 13, 2025 4:52 AM

07:19 AM EDT, 08/13/2025 (MT Newswires) -- Metro (MRU.TO) on Wednesday said third-quarter adjusted earnings and sales advanced, but missed estimates.

Adjusted net earnings, which excludes most one-time items, rose 8.8% to $331.8 million, or $1.52 per diluted share, from $305 million, or $1.35 per diluted share, in the prior-year period. The result missed the consensus analyst estimate of $1.53 per share, according to FactSet.

Quarterly sales increased 3.3% to $6.87 billion, missing the $6.92 billion forecast. Food same-store sales were up 1.9%. Pharmacy same-store sales were up 5.5%, with a 6.2% increase in prescription drugs and a 4% increase in front-store sales.

The board declared a quarterly dividend of $0.37 per share.

"We are pleased with our results in the third quarter, marked by solid comparable sales growth in food and pharmacy, and good cost control. We successfully opened five new food stores in the quarter, a pace that will continue in the fourth quarter, on track with our plan to accelerate the development of our growing discount banners," said Eric La Fleche, president and chief executive officer.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
Jun 16, 2025
(Reuters) -Eli Lilly ( LLY ) is in advanced talks to acquire gene editing startup Verve Therapeutics ( VERV ) for up to $1.3 billion, aiming to strengthen its pipeline of experimental medicines, the Financial Times reported on Monday. The drug maker's acquisition bid includes a payment of almost $1 billion upfront for Verve, and a further $300 million based...
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
Jun 16, 2025
June 16 (Reuters) - Eli Lilly ( LLY ) is in advanced talks to acquire gene editing startup Verve Therapeutics ( VERV ) for up to $1.3 billion, aiming to strengthen its pipeline of experimental medicines, the Financial Times reported on Monday. The drug maker's acquisition bid includes a payment of almost $1 billion upfront for Verve, and a further...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Ecuador reopens mining concession registry after seven years
Ecuador reopens mining concession registry after seven years
Jun 16, 2025
QUITO (Reuters) -Ecuador's mining ministry announced on Monday the launch of a new registry of concessions for the first time in seven years in an effort to attract more mining projects to the South American country and curb illegal operations. The prior registry was shut down in 2018 over concerns of irregularities in the concession system, and no new concessions...
Copyright 2023-2026 - www.financetom.com All Rights Reserved